SCHEMBL21363431

SCHEMBL21363431

CC(C)(C)n1cnc2cnccc2c1=O

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 3/20 0.42
KDM4A O75164 1/20 0.42
KDM4B O94953 1/20 0.42
KDM5C P41229 1/20 0.42
KDM5B Q9UGL1 1/20 0.42
KDM3A Q9Y4C1 1/20 0.42
IDO1 P14902 3/20 0.40
TRPA1 O75762 1/20 0.39
CHRM1 P11229 1/20 0.36
LATS1 O95835 5/20 0.35
LATS2 Q9NRM7 4/20 0.35
MAPK13 O15264 1/20 0.35
MAPK12 P53778 1/20 0.35
MAPK11 Q15759 1/20 0.35
MAPK14 Q16539 1/20 0.35
USP7 Q93009 1/20 0.35
KDM5A P29375 2/20 0.35
FGFR1 P11362 1/20 0.34
HCAR1 Q9BXC0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10328321 0.78 KDM4C (0.46) KDM4CKDM4AKDM4BKDM5CKDM5B
SCHEMBL122153 0.78 POLB (0.51)
SCHEMBL9925635 0.76 FGFR1 (0.49) MAPK13MAPK12MAPK11MAPK14FGFR1
SCHEMBL38665823 0.75 KDM4C (0.46) KDM4CKDM4AKDM4BKDM5CKDM5B
SCHEMBL26201351 0.75 KDM4C (0.46) KDM4CKDM4AKDM4BKDM5CKDM5B
SCHEMBL21363538 0.74 TRPA1 (0.37) TRPA1MAPK13MAPK12MAPK11MAPK14
SCHEMBL22477637 0.74 USP5 (0.46) KDM4CKDM4AKDM4BKDM5CKDM5B
SCHEMBL21363472 0.74 TRPA1 (0.49) KDM4CKDM4AKDM4BKDM5CKDM5B
SCHEMBL10280661 0.73 MAPK13 (0.39) MAPK13MAPK12MAPK11MAPK14FGFR1
SCHEMBL21363471 0.71 TRPA1 (0.37) TRPA1HCAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2023-05-23 US disclosed
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2023-04-20 US disclosed
US-20200308161-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2020-10-01 US disclosed
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors GENENTECH, INC. (US) 2020-07-14 US disclosed
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS GENENTECH, INC. (US) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10711004-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 KDM4C 4605/4885KDM4A 4306/4885KDM4B 4251/4885
US-11655245-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, P2RX3 KDM4C 4151/4885KDM4A 3354/4885KDM4B 3642/4885
US-20190284179-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 KDM4C 4313/4885KDM4A 3596/4885KDM4B 3912/4885
US-20200308161-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, P2RX3 KDM4C 4151/4885KDM4A 3354/4885KDM4B 3642/4885
US-10710994-B2 Oxadiazole transient receptor potential channel inhibitors TRPA1, TRPV1, TRPV3 KDM4C 4313/4885KDM4A 3596/4885KDM4B 3912/4885
US-20230121700-A1 OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS TRPA1, TRPV1, TRPV3 KDM4C 4313/4885KDM4A 3596/4885KDM4B 3912/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.